Total Payments
$7,918
2024 Payments
$1,351
Companies
55
Transactions
478
Medicare Patients
5,910
Medicare Billing
$1.2M
Payment Breakdown by Category
Food & Beverage$7,907 (99.9%)
Education$10.62 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,907 | 475 | 99.9% |
| Education | $10.62 | 3 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $1,011 | 62 | $0 (2024) |
| Lilly USA, LLC | $838.43 | 54 | $0 (2024) |
| ABBVIE INC. | $760.67 | 57 | $0 (2024) |
| Novo Nordisk Inc | $604.77 | 41 | $0 (2024) |
| Abbott Laboratories | $371.37 | 17 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $342.72 | 19 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $275.42 | 20 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $264.92 | 13 | $0 (2022) |
| Avanir Pharmaceuticals, Inc. | $256.25 | 13 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $250.39 | 13 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,351 | 74 | Lilly USA, LLC ($203.55) |
| 2023 | $1,314 | 74 | ABBVIE INC. ($255.54) |
| 2022 | $1,011 | 63 | Lilly USA, LLC ($228.13) |
| 2021 | $1,371 | 92 | GlaxoSmithKline, LLC. ($216.72) |
| 2020 | $1,187 | 71 | GlaxoSmithKline, LLC. ($313.32) |
| 2019 | $683.42 | 42 | GlaxoSmithKline, LLC. ($157.16) |
| 2018 | $417.78 | 24 | Novartis Pharmaceuticals Corporation ($76.49) |
| 2017 | $581.99 | 38 | Boehringer Ingelheim Pharmaceuticals, Inc. ($128.16) |
All Payment Transactions
478 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.99 | General |
| Category: NEUROSCIENCE | ||||||
| 11/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.25 | General |
| Category: DIABETES | ||||||
| 11/24/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $28.33 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/18/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $23.12 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/11/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $25.05 | General |
| Category: PSYCHIATRY | ||||||
| 10/29/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.40 | General |
| Category: Diabetes | ||||||
| 10/21/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $19.24 | General |
| Category: NEUROSCIENCE | ||||||
| 10/15/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $20.93 | General |
| Category: Cardio-renal | ||||||
| 10/03/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $8.47 | General |
| Category: NEUROSCIENCE | ||||||
| 09/24/2024 | Philips North America LLC | (CK7) Extended Holter (Device) | Food and Beverage | Cash or cash equivalent | $25.22 | General |
| Category: Medical Device | ||||||
| 09/20/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $17.07 | General |
| Category: Psychology/Psychiatric | ||||||
| 09/16/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $20.10 | General |
| Category: Cardio-renal | ||||||
| 09/16/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $18.99 | General |
| Category: NEUROLOGY | ||||||
| 09/16/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.02 | General |
| Category: NEUROSCIENCE | ||||||
| 09/10/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.83 | General |
| 09/06/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $10.20 | General |
| Category: Diabetes | ||||||
| 08/30/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $21.91 | General |
| Category: Biological | ||||||
| 08/29/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $14.52 | General |
| Category: Oncology | ||||||
| 08/27/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: NEUROSCIENCE | ||||||
| 08/26/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.40 | General |
| Category: Diabetes | ||||||
| 08/23/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $13.63 | General |
| Category: Diabetes | ||||||
| 08/20/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $9.62 | General |
| Category: NEUROSCIENCE | ||||||
| 08/19/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $19.27 | General |
| Category: NEUROSCIENCE | ||||||
| 08/08/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.52 | General |
| Category: Cardio-renal | ||||||
| 08/06/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $17.74 | General |
| Category: VACCINES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 1,465 | 5,969 | $944,870 | $325,922 |
| 2022 | 28 | 1,722 | 20,001 | $922,588 | $318,540 |
| 2021 | 26 | 1,250 | 21,940 | $472,573 | $255,702 |
| 2020 | 26 | 1,473 | 20,419 | $573,408 | $280,175 |
Total Patients
5,910
Total Services
68,329
Medicare Billing
$1.2M
Procedure Codes
104
All Medicare Procedures & Services
104 procedure records from CMS Medicare Utilization — Page 3 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2022 | 25 | 132 | $2,440 | $41.31 | 1.7% |
| 96127 | Assessment of emotional or behavioral problems | Office | 2022 | 11 | 11 | $220.00 | $37.98 | 17.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 63 | 1,068 | $160,572 | $86,078 | 53.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 194 | 478 | $74,606 | $41,974 | 56.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 201 | 649 | $52,285 | $38,014 | 72.7% |
| 99309 | Subsequent nursing facility visit, typically 25 minutes per day | Facility | 2021 | 85 | 417 | $42,300 | $26,249 | 62.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 44 | 223 | $32,160 | $12,475 | 38.8% |
| 99496 | Transitional care management services, highly complexity, requiring face-to-face visits within 7 days of discharge | Office | 2021 | 52 | 74 | $12,210 | $9,768 | 80.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 53 | 59 | $13,275 | $9,258 | 69.7% |
| 99306 | Initial nursing facility visit, typically 45 minutes per day | Facility | 2021 | 54 | 56 | $11,025 | $7,250 | 65.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 57 | 66 | $11,726 | $6,457 | 55.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 44 | 49 | $8,685 | $4,048 | 46.6% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 84 | 354 | $17,700 | $3,542 | 20.0% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2021 | 45 | 75 | $4,474 | $2,658 | 59.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 14 | 14 | $6,300 | $1,779 | 28.2% |
| 99310 | Subsequent nursing facility visit, typically 35 minutes per day | Facility | 2021 | 14 | 16 | $2,480 | $1,503 | 60.6% |
| 99308 | Subsequent nursing facility visit, typically 15 minutes per day | Facility | 2021 | 24 | 28 | $2,180 | $1,092 | 50.1% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 11 | 30 | $1,289 | $946.82 | 73.5% |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 2021 | 32 | 165 | $2,475 | $793.61 | 32.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 26 | 26 | $780.00 | $411.32 | 52.7% |
| J1071 | Injection, testosterone cypionate, 1 mg | Office | 2021 | 11 | 17,425 | $8,713 | $385.92 | 4.4% |
| 90756 | Vaccine for influenza derived from cell cultures for injection into muscle, quadrivalent, antibiotic free, 0.5ml dosage | Office | 2021 | 12 | 12 | $420.00 | $340.44 | 81.1% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2021 | 28 | 153 | $2,295 | $231.83 | 10.1% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 21 | 22 | $483.56 | $230.64 | 47.7% |
| 81002 | Urinalysis, manual test | Office | 2021 | 22 | 29 | $580.00 | $100.92 | 17.4% |
About Dr. Mark Mouton, M.D
Dr. Mark Mouton, M.D is a Internal Medicine healthcare provider based in Baker, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/07/2007. The National Provider Identifier (NPI) number assigned to this provider is 1164613758.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Mouton, M.D has received a total of $7,918 in payments from pharmaceutical and medical device companies, with $1,351 received in 2024. These payments were reported across 478 transactions from 55 companies. The most common payment nature is "Food and Beverage" ($7,907).
As a Medicare-enrolled provider, Mouton has provided services to 5,910 Medicare beneficiaries, totaling 68,329 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 104 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Baker, LA
- Active Since 08/07/2007
- Last Updated 06/29/2014
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1164613758
Products in Payments
- TRELEGY ELLIPTA (Drug) $787.61
- VRAYLAR (Drug) $707.00
- JARDIANCE (Drug) $366.65
- Ozempic (Drug) $291.34
- REXULTI (Drug) $283.13
- TRULICITY (Drug) $281.70
- TRINTELLIX (Drug) $252.82
- NUEDEXTA (Drug) $239.27
- FREESTYLE LIBRE 3 (Device) $236.73
- MOUNJARO (Drug) $164.95
- Veozah (Drug) $161.19
- ENTRESTO (Drug) $158.76
- Aimovig (Biological) $145.81
- RYBELSUS (Drug) $141.53
- QULIPTA (Drug) $133.84
- MYDAYIS (Drug) $131.51
- Kerendia (Drug) $124.75
- EMGALITY (Drug) $119.72
- XARELTO (Drug) $118.68
- AUSTEDO (Drug) $113.28
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.